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Introduction
Chronic hepatitis C and hepatitis B infections are more 
common in people with HIV than those without HIV [1]. 
Co-infection with HIV and viral hepatitis increases both 
the likelihood and rate of progression to cirrhosis, hepato-
cellular carcinoma and end-stage liver disease compared to 
either HIV infection or hepatitis mono-infection alone [2, 
3]. Liver disease is a leading cause of death in HIV-posi-
tive individuals [1], and is thus responsible for a consider-
able mortality burden particularly in countries where wide-
spread access to combination antiretroviral therapy (cART) 
has drastically reduced numbers of deaths from AIDS.
Historically, liver transplantation—an important treat-
ment option for patients with end-stage liver disease—has 
been successful in the context of HBV/HIV co-infection 
[4] but has carried poor outcomes in HIV/HCV co-infected 
patients. This was principally due to poor patient and graft 
survival as the immunosuppression required to prevent 
organ rejection frequently resulted in infectious complica-
tions as well as aggressive HCV recurrence [5]. Now, as 
well as improved survival in HIV-positive persons due to 
cART, recent advances in the treatment of hepatitis C with 
directly acting antiviral agents (DAAs) and prophylaxis of 
opportunistic infections mean that liver transplantation may 
be an increasingly viable option for co-infected patients 
with end-stage liver disease [6].
Recent clinical practice around liver transplantation 
in co-infected patients in the United Kingdom, however, 
remains unclear. Here we aimed to describe the likelihood 
of referral for liver transplantation assessment in a cohort 
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of co-infected patients with complications of cirrhosis seen 
from 2004 onwards, using linked routine data from multi-
ple UK centres.
Methods
Study design, setting and participants
A cohort of co-infected patients with cirrhosis was drawn 
from a sub-study of 11 centres from the United Kingdom 
Collaborative HIV Cohort (UK CHIC) study—a multi-
centre prospective cohort study collecting routine clinical 
and treatment data on HIV-positive individuals [7]. Pseu-
donymised data are collected annually from all partici-
pating centres. UK CHIC data are also updated each year 
using linked HIV surveillance datasets from Public Health 
England, which are linked to national death registry data. 
Individuals in the hepatitis sub-study had evidence of either 
hepatitis B, defined as ever receiving a positive hepatitis B 
surface antigen or positive HBV-DNA test, or hepatitis C 
infection, defined as ever receiving a positive hepatitis C 
antibody test or a positive hepatitis C RNA test, and had 
received care at one of 11 tertiary centres in England and 
Scotland from 2004 onwards. Cirrhosis was defined as 
either a confirmed diagnosis (APRI score >2; biopsy with 
Ishak score of 5 or 6; biopsy with METAVIR score = 4; 
FibroScan with result >14 kPa), or a scan result suggestive 
of cirrhosis. We also included data on co-infected patients 
with hepatocellular carcinoma (HCC). Supplementary 
data were collected on clinical outcomes of co-infection 
including decompensation events identified through medi-
cal records review between September 2012 and September 
2013 at the included centres. The UK CHIC dataset was 
enriched by collecting additional data on liver transplant 
assessments and outcomes in co-infected patients occur-
ring up to December 2014 from three major liver transplant 
centres: King’s Liver Transplant Unit, the Sheila Sherlock 
Liver Centre at the Royal Free London NHS Foundation 
Trust and the Scottish Liver Transplant Unit based at the 
Royal Infirmary of Edinburgh. These centres are responsi-
ble for 44% of liver transplants carried out in the UK [8] 
and cover similar geographical areas to the HIV treatment 
centres contributing data to the UK CHIC study. This meth-
odology was previously used to investigate outcomes of 
end-stage kidney disease in UK CHIC participants [9].
Data linkage
Data from liver transplant units were linked to data from 
the UK CHIC hepatitis sub-study using a deterministic 
n-1 approach with the matching variables day of birth, 
month of birth, year of birth, gender, hepatitis B status and 
hepatitis C status, i.e., a match was considered true if at 
least five of these six variables matched. In addition, true 
matches could not have a death date recorded in either UK 
CHIC or transplant data before the end of follow-up in the 
other dataset.
This approach allowed for minor data entry errors, 
missing data fields to be present and time lags between 
the two datasets in which hepatitis B or C recorded status 
could change with serological resolution of infection or re-
infection/reactivation. A total of 48 records from transplant 
units were collected, of which 34 (70.8%) matched to a 
UK CHIC record. Of the 34 matched records, 14 (41.2%) 
matched on all 6 fields and 20 (58.8%) matched on 5 fields 
but were considered likely to be true matches by manual 
record review.
Statistical analysis
We described the proportion of co-infected patients with 
cirrhosis experiencing complications (either decompen-
sation or HCC), the proportion referred for transplant 
assessment and receiving a transplant stratified by the 
presence or absence of complications, and the proportion 
that died during follow-up in UK CHIC. χ2 tests were used 
to compare outcomes by clinical or demographic vari-
ables such as gender, age group and infection status. We 
also described characteristics of those referred for trans-
plant including stages of liver disease using UKELD [10], 
MELD and Child Pugh scoring systems, and assessed dif-
ferences in those with repeated measures at assessment 
and transplant using paired t tests. We did not undertake 
further analysis on any sub-group containing fewer than 
10 individuals to reduce the risk of any individual being 
identified, as per research ethics committee guidance. All 
analyses were conducted using Stata version 13 (StataCorp 
LP, College Station, TX).
Results
Of 4659 people co-infected with hepatitis B or C in the 
UK CHIC study, 575 (12.3%) had confirmed cirrhosis, a 
further 190 (4.1%) had imaging suggestive of cirrhosis 
and 7 (0.15%) had HCC but no cirrhosis record. For these 
772 patients, 141 (18.3%) had at least one complication 
of cirrhosis recorded, rising to 29.2% in triple infected 
patients. For the 141 patients with a complication of cir-
rhosis recorded, median age was 44.6 years (IQR 40.1–
49.3 years), 83.7% were male and median follow-up time 
was 13.1 years (IQR 6.2–18.7 years). Demographic and 
clinical characteristics stratified by infection status are 
shown in Table 1 for the cirrhosis cohort with and without 
recorded complications.
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For patients with a complication recorded, the propor-
tion referred for liver transplantation assessment was 
23/141 (16.3%). The corresponding proportion for patients 
with no record of complications (who may not meet refer-
ral criteria) was 15/631 (2.4%). Of these 38 patients with 
evidence of referral for transplant assessment, this was 
based on either transplant unit data alone (n = 27), trans-
plant and UK CHIC data (n = 6) or UK CHIC data denot-
ing a previous transplant (n = 5). The proportions receiv-
ing a transplant assessment did not differ significantly by 
gender (p = 0.09), age group (p = 0.67) or infection status 
(p = 0.31). Although numbers were small, there was some 
evidence that referrals increased over time: there were 8 
referrals between 2003 and 2006, 10 referrals between 
2007 and 2010 and 14 referrals between 2011 and 2014; 
a further 6 had no recorded transplant assessment date. Of 
patients with transplant unit data who were assessed, 22 
(66.7%) were accepted onto the transplant list, three were 
deferred (9.1%) and eight (24.2%) were not accepted. Rea-
sons given for not accepting patients onto the transplant 
list included being too well, psychosocial reasons such as 
ongoing drug or alcohol use, and alternative management 
decisions, e.g., tumour resection for some patients with 
HCC. Four patients on the list were delisted before trans-
plant for similar reasons.
There were 25 patients with recorded cirrhosis or 
HCC who had evidence of receiving a liver transplant 
(14 from transplant unit data alone, six from transplant 
and UK CHIC data and five from UK CHIC data alone), 
which included some patients initially deferred or not 
accepted onto the list at first assessment. Among those 
assessed, receiving a transplant was not associated with 
age group (p = 0.90), gender (p = 0.75) or infection sta-
tus (p = 0.99). Where data were available from transplant 
Table 1  Characteristics of 772 co-infected patients with cirrhosis or HCC in the UK CHIC Study
a n = 765 for method of cirrhosis diagnosis. An additional seven patients had evidence of HCC alone
b Suppressed due to small numbers
Characteristic HIV/hepatitis B, n (%) HIV/hepatitis C, n (%) HIV/hepatitis B and C, n (%) Total, n (%)
Gender
 Male 177 (86.3) 400 (83.7) 80 (89.9) 657 (85.1)
 Female 28 (13.7) 78 (16.3) 9 (10.1) 115 (14.9)
Age at cirrhosis/HCC diagnosis (years)
 <30 9 (4.4) 32 (6.7) 4 (4.5) 45 (5.8)
 30–34.9 28 (13.7) 54 (11.3) 16 (18.0) 98 (12.7)
 35–39.9 33 (16.1) 93 (19.5) 16 (18.0) 142 (18.4)
 40–44.9 48 (23.4) 119 (24.9) 20 (22.5) 187 (24.2)
 45–49.9 47 (22.9) 98 (20.5) 17 (19.1) 162 (21.0)
 50–54.9 21 (10.2) 47 (9.8) 10 (11.2) 78 (10.1)
 55+ 19 (9.3) 35 (7.3) 6 (6.7) 60 (7.8)
Method of cirrhosis diagnosis (n = 765)a
 APRI score 71 (35.3) 289 (60.5) 27 (31.4) 387 (50.6)
 Liver biopsy 32 (15.9) 60 (12.6) 25 (29.1) 117 (15.3)
 Fibroscan 12 (6.0) 44 (9.2) 15 (17.4) 71 (9.3)
 Imaging suggestive of cirrhosis 86 (42.8) 85 (17.8) 19 (22.1) 190 (24.8)
Complication (at least one episode)
 Ascites 16 (7.7) 36 (7.5) 10 (11.2) 62 (8.0)
 Portal hypertension 28 (13.6) 50 (10.5) 16 (18.0) 94 (12.2)
 Varices ± haematemesis 30 (14.6) 52 (10.9) 18 (20.2) 100 (12.9)
 Encephalopathy b b b 6 (0.8)
 Hepatocellular carcinoma 17 (8.3) 8 (1.7) 5 (5.6) 30 (3.9)
 Any of the above 46 (22.3) 69 (14.4) 26 (29.2) 141 (18.2)
Death
 Yes 33 (16.1) 73 (15.3) 13 (14.6) 119 (15.4)
 No 172 (83.9) 405 (84.7) 76 (85.4) 653 (84.6)
Median time to death from cirrhosis or HCC 
diagnosis (IQR) (years)
3.4 (0.6–6.8) 3.2 (0.7–7.1) 3.1 (1.2–5.1) 3.3 (0.7–6.7)
Total 205 (26.6) 478 (61.9) 89 (11.5) 772 (100.0)
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units (20 individuals), the median waiting time from date of 
referral for assessment to transplant was 6.7 months (IQR 
4.5–11.2). For these 20 patients, 25% had evidence of at 
least one episode of decompensation while on the trans-
plant waiting list, 50% had no episodes, with no data on 
decompensation available for the remaining 25%. Charac-
teristics of patients at the time of assessment and transplant 
are shown in Table 2.
There were 57 deaths among people with a complication 
recorded at any time during follow-up (40.4%) compared 
to 62 deaths among those with no complications recorded 
(9.8%). Results were similar when stratifying by transplant 
status: 42.9% with a complication died versus 0% without 
a complication among patients with a transplant recorded; 
corresponding results for those with no transplant record 
were 40.2 versus 10%, respectively. There were no signifi-
cant differences in the proportion who died between those 
who did and did not have a record of transplant (p = 0.23). 
The proportion of patients who died also did not dif-
fer by gender (p = 0.53), age at cirrhosis/HCC diagnosis 
(p = 0.47) or infection status (p = 0.94). It was not pos-
sible, however, to investigate survival in detail due to dif-
ferences in follow-up time between those with and without 
transplant data.
Discussion
In our cohort of co-infected patients with complications 
of cirrhosis, the proportion referred for liver transplanta-
tion assessment was low (16.3%), even after enriching the 
dataset with additional data from transplant centres. Sur-
vival of HIV/HCV co-infected patients with decompen-
sated cirrhosis without liver transplantation was extremely 
poor in the pre-DAA era (median = 16 months after first 
decompensation episode) [11]. Current British HIV Asso-
ciation guidelines recommend that patients with HIV/viral 
hepatitis co-infection with cirrhosis should be referred for 
transplantation assessment early, and no later than after first 
decompensation [12]. Our work highlights the need to opti-
mise current management of end-stage liver disease in this 
patient population.
The reasons for low rates of referrals for transplant 
assessment in patients with HIV/HBV coinfection are not 
clear, given that transplant results are excellent, with no dif-
ference in patient and graft survival between HBV mono-
infected and HBV/HIV co-infected individuals [4]. In con-
trast, it is possible that concerns over poor liver transplant 
outcome in patients with HIV/HCV co-infection may have 
contributed to clinician reluctance to refer. In studies prior 
to the advent of DAAs, these individuals experienced lower 
patient and graft survival and higher rates of acute rejection 
than patients with HCV mono-infection [13–15]. In HIV/
HCV co-infected patients post-transplant, HCV recurrence 
is the main cause of death [14, 15] and clearance of HCV 
virus dramatically improves survival [15].
Outcomes in HIV/HCV are likely to improve in the 
DAA era such that patients with HIV/HCV should be able 
to achieve an HCV cure either before a transplant is neces-
sary or post-transplant. Clinical trials of DAAs show excel-
lent sustained virologic response (SVR) rates in HIV/HCV 
co-infected patients across all genotypes that are similar or 
better than those seen in HCV mono-infected patients [16, 
17]. There is also evidence that treating HCV with DAAs 
in the post-transplant setting in HCV mono-infection can 
achieve SVR in the majority of patients [18].
Strengths of our study include drawing on a large HIV 
patient cohort from multiple centres around the UK with 
detailed long-term follow-up on liver disease diagnoses and 
management. Collecting additional data from three major 
liver transplant units improved ascertainment of referrals 
for transplant assessments. The transplant units covered 
similar geographical areas to the HIV treatment centres 
contributing data to the UK CHIC study so it is likely that 
most patients in the CHIC study referred for liver transplan-
tation assessment would have been referred to one of these 
units. This method of linking data from transplant units to 
UK CHIC data has previously been used successfully to 
Table 2  Characteristics of patients assessed for and receiving liver transplants
a An additional five patients with CHIC data on transplants did not have information on stage of liver disease by UKELD, MELD or Child Pugh 
score, or details of BMI or length of hospital stay
± From paired t test for individuals with measures at both assessment and transplant
Characteristic Referred for transplant (n = 33), median (IQR) Had a transplant (n = 20)a, median (IQR) p value±
UKELD score 55 (51–63) 58.5 (48–66.3) 0.69
MELD score 14 (10–21) 14 (9–27) 0.34
Child Pugh score 9 (6.5–10.5) 9.5 (6–12) 0.45
Body mass index – 23.5 (21.6–26.0) –
ICU duration (days) – 3.5 (2–9) –
Total duration of stay (days) – 20.5 (15.8–30.5) –
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investigate rates of kidney transplantation in the context of 
HIV infection [9].
There are, however, several limitations to our study. 
The specificity of a cirrhosis diagnosis varied depending 
on the method used: we recognise that the APRI score 
has less diagnostic accuracy in co-infected patients com-
pared to mono-infected patients, and some patients were 
included based on imaging suggestive of cirrhosis. We 
adopted an intentionally broad definition for inclusivity, 
but recognised that not all would meet criteria for liver 
transplantation. Lack of data on other parameters such 
as MELD score in patients without linked transplant unit 
data meant that the exact number eligible for transplant 
was uncertain. Nevertheless, the proportion referred 
for transplant assessment was low when restricting to 
patients with evidence of decompensation. This limited 
statistical power to detect differences in outcomes by 
factors such as co-infection status. There may also have 
been incomplete recording of decompensation events 
in UK CHIC data: previous studies have shown varying 
rates of decompensation among HCV/HIV co-infected 
individuals ranging from 5.8% among all co-infected 
individuals [19] to 23% among cirrhotic co-infected indi-
viduals [20], but varying lengths of follow-up make these 
difficult to compare across studies. Incomplete recording 
of decompensation in UK CHIC data would, however, 
artificially increase rather than decrease the proportion 
referred for liver transplantation assessment. Finally, dif-
fering lengths of follow-up time between patients with 
UK CHIC data alone and those who had additional trans-
plant unit data limited the scope for conducting survival 
analysis.
In conclusion, we show that management of decompen-
sated cirrhosis in co-infected individuals in the UK is sub-
optimal due to the low proportions of patients referred for 
and receiving liver transplantation. The recent revolution 
in antiviral treatments for hepatitis C means that clinicians 
must ensure that co-infected patients have the opportunity 
for early transplant assessment to facilitate optimal and 
timely management of their end-stage liver disease.
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